Piramal Pharma Solutions Invests Millions in New Amsterdam Pharma FDC Facility

Piramal Pharma Solutions has invested several million dollars to provide commercial capabilities for the fixed-dose combination (FDC) of Obicetrapib and Ezetimib to meet potentially high commercial demand. The company has utilized the strength of two additional facilities to efficiently manufacture FDC and demonstrated the benefits of its integrated development approach. This investment will enable Piramal Pharma Solutions to support the commercialization of the FDC and help meet the growing demand for the product.

Piramal Pharma Solutions has announced a significant investment in its Sellersville, Pennsylvania, facility, aimed at enhancing its oral solid dosage (OSD) production capabilities. This move is part of a strategic partnership with NewAmsterdam Pharma to meet potentially high commercial demand for a fixed-dose combination (FDC) of obicetrapib and ezetimibe [1].

The multi-million-dollar investment includes the development of a dedicated OSD suite, equipped with advanced capabilities for granulation, compression, tableting, and coating. This new suite will focus on the production of NewAmsterdam Pharma's investigational FDC, a non-statin cholesterol medication designed to reduce LDL-C levels [2].

Piramal's CEO, Peter DeYoung, expressed enthusiasm about the expansion, stating, "We are thrilled to expand our OSD production capabilities at the Sellersville facility with this new manufacturing suite. This addition will not only enhance our production capacity and speed but also reinforce our commitment to patient centricity" [2].

The suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, which is currently undergoing clinical trials. The partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond the Sellersville site, with other facilities in Ahmedabad and Pithampur, India, playing crucial roles in the product's development and dual sourcing support [2].

The investment is expected to create more than 20 new jobs at the Sellersville site over the next five years, contributing to the local economy and workforce. This commitment to continuous improvement underscores the collaborative efforts between Piramal Pharma Solutions and NewAmsterdam Pharma to operate with greater efficiency and capacity, ultimately bringing the FDC product to more patients in need [2].

References:

[1] Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville Pennsylvania Site. (2025). Retrieved from https://www.prnewswire.com/news-releases/piramal-pharma-solutions-and-newamsterdam-pharma-invest-in-dedicated-suite-to-enhance-oral-solid-dosage-production-capabilities-at-piramals-sellersville-pennsylvania-site-302535566.html

[2] Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville Pennsylvania Site. (2025). Retrieved from https://www.biospace.com/press-releases/piramal-pharma-solutions-and-newamsterdam-pharma-invest-in-dedicated-suite-to-enhance-oral-solid-dosage-production-capabilities-at-piramals-sellersville-pennsylvania-site